Canaccord lowered the firm’s price target on Taysha Gene Therapies to $7 from $13 and keeps a Buy rating on the shares. The firm continues to like the setup for the shares for the remainder of this year and next with more to come from Rett via quarterly updates and regulatory feedback on its lead TSH-120 program in GAN.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TSHA:
- Taysha Gene Therapies price target raised to $6 from $2 at Truist
- Taysha Gene Therapies price target raised to $8 from $6 at Baird
- Why Taysha Gene Therapies (NASDAQ:TSHA) Doubled Its Value Today
- Cantor ups Taysha target to $7 from $2 after ‘robust’ Rett data
- Taysha Gene Therapies price target raised to $7 from $2 at Cantor Fitzgerald